dr. rizvi discusses pembrolizumab for non-small cell lung cancer
Published 9 years ago • 482 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
1:26
dr. rizvi on activity and toxicity of pembrolizumab for nsclc
-
1:29
dr. rizvi on utilizing molecular characteristics to inform treatment decisions in nsclc
-
0:56
dr. rizvi on the utility of trastuzumab deruxtecan in nsclc
-
4:47
immune checkpoint inhibitors in small-cell lung cancer
-
0:50
dr. rizvi on pseudoprogression in lung cancer after immunotherapy
-
1:15
dr. rizvi on pd-1 and pd-l1 inhibitors in lung cancer
-
1:15
dr. rizvi on nivolumab plus erlotinib in patients with egfr mt nsclc
-
1:18
dr. reck on the safety of pembrolizumab in keynote-024 in metastatic nsclc
-
5:00
implications for pembrolizumab in nsclc
-
1:50
dr. levy discusses pembrolizumab in nsclc
-
7:22
pd-1 inhibition in lung cancer
-
7:01
actual use of pembrolizumab and chemotherapy in nsclc
-
0:53
dr. sequist on pembrolizumab monotherapy in nonsquamous nsclc
-
1:48
dr. brahmer discusses frontline single-agent pembrolizumab in lung cancer
-
1:00
dr. papadimitrakopoulou provides an update on pembrolizumab for lung cancer
-
5:54
pembrolizumab in newly diagnosed squamous nsclc
-
2:12
dr. mok discusses updated data with pembrolizumab in nsclc
-
2:15
dr. ramalingam on pembrolizumab and chemotherapy in nsclc
-
1:41
dr. brahmer discusses second-line pembrolizumab in nsclc